Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368162 | 1.00 | CYP3A4 (0.59) | CYP3A4ALDH1A1TP53MAOBRXRA | |
| 3-Aminophenol SCHEMBL2372737 | 0.89 | ALDH1A1 (0.59) | CYP3A4ALDH1A1TP53MAOBRXRA | |
| SCHEMBL20557906 | 0.88 | RXRA (0.57) | CYP3A4ALDH1A1TP53RXRARXRB | |
| SCHEMBL30469319 | 0.88 | RXRA (0.57) | CYP3A4ALDH1A1TP53RXRARXRB | |
| SCHEMBL4649436 | 0.87 | ALDH1A1 (0.59) | CYP3A4ALDH1A1TP53MAOBCASP1 | |
| SCHEMBL2968363 | 0.84 | RXRA (0.53) | ALDH1A1TP53RXRARXRBDHFR | |
| SCHEMBL10582109 | 0.83 | CYP3A4 (0.61) | CYP3A4ALDH1A1TP53MAOBCASP1 | |
| SCHEMBL23951643 | 0.80 | ALDH1A1 (0.52) | CYP3A4ALDH1A1TP53MAOBCASP1 | |
| SCHEMBL15458083 | 0.80 | CYP3A4 (0.56) | CYP3A4ALDH1A1TP53MAOBCASP1 | |
| SCHEMBL21693963 | 0.80 | ALDH1A1 (0.52) | CYP3A4ALDH1A1TP53MAOBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 723 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903168-A | Pyrrolo [2,3-d ] thiazole derivatives, and preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | claimed |
| WO-2023057548-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-04-13 | — | — | WO | claimed |
| WO-2022117389-A1 | METHOD FOR PRODUCING A TERMINAL-FUNCTIONAL POLYMER | BASF SE (DE) | 2022-06-09 | — | — | WO | claimed |
| CN-110961151-A | Ruthenium-copper bimetallic catalyst, preparation method and application thereof | 扬州大学 | 2020-04-07 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| CN-106187779-B | A kind of method for synthesizing aromatic nitro compound | 常州大学 | 2018-06-26 | — | — | CN | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-2188289-A2 | (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | Lexicon Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2009021169-A2 | (7H-PYRR0L0 [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | LEXICON PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | WO | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | claimed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | CYP3A4 403/4885ALDH1A1 1197/4885TP53 4736/4885 |
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | CYP3A4 97/4885ALDH1A1 841/4885TP53 2291/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | CYP3A4 403/4885ALDH1A1 1197/4885TP53 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.